As of 2025-06-16, the Relative Valuation of Myriad Genetics Inc (MYGN) is (14.80) USD. This relative valuation is based on P/E multiples. With the latest stock price at 5.03 USD, the upside of Myriad Genetics Inc based on Relative Valuation is -394.1%.
The range of the Relative Valuation is (11.37) - (16.19) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.3x - 18.4x | 14.3x |
| Forward P/E multiples | 9.9x - 14.7x | 12.6x |
| Fair Price | (11.37) - (16.19) | (14.80) |
| Upside | -326.1% - -421.9% | -394.1% |
| Date | P/E |
| 2025-06-13 | -4.57 |
| 2025-06-12 | -4.72 |
| 2025-06-11 | -4.71 |
| 2025-06-10 | -4.75 |
| 2025-06-09 | -4.72 |
| 2025-06-06 | -4.63 |
| 2025-06-05 | -4.47 |
| 2025-06-04 | -4.81 |
| 2025-06-03 | -4.44 |
| 2025-06-02 | -4.05 |
| 2025-05-30 | -3.81 |
| 2025-05-29 | -3.78 |
| 2025-05-28 | -3.94 |
| 2025-05-27 | -3.77 |
| 2025-05-23 | -3.55 |
| 2025-05-22 | -3.57 |
| 2025-05-21 | -3.70 |
| 2025-05-20 | -4.05 |
| 2025-05-19 | -4.03 |
| 2025-05-16 | -3.75 |
| 2025-05-15 | -3.74 |
| 2025-05-14 | -3.49 |
| 2025-05-13 | -3.74 |
| 2025-05-12 | -3.86 |
| 2025-05-09 | -3.54 |
| 2025-05-08 | -3.66 |
| 2025-05-07 | -3.88 |
| 2025-05-06 | -6.61 |
| 2025-05-05 | -7.00 |
| 2025-05-02 | -6.87 |
| 2025-05-01 | -6.48 |
| 2025-04-30 | -6.74 |
| 2025-04-29 | -6.55 |
| 2025-04-28 | -6.82 |
| 2025-04-25 | -6.75 |
| 2025-04-24 | -6.70 |
| 2025-04-23 | -6.63 |
| 2025-04-22 | -6.75 |
| 2025-04-21 | -6.73 |
| 2025-04-17 | -6.95 |
| 2025-04-16 | -7.19 |
| 2025-04-15 | -7.28 |
| 2025-04-14 | -7.35 |
| 2025-04-11 | -7.27 |
| 2025-04-10 | -7.23 |
| 2025-04-09 | -7.68 |
| 2025-04-08 | -7.03 |
| 2025-04-07 | -7.34 |
| 2025-04-04 | -7.39 |
| 2025-04-03 | -7.65 |